Dasatinib

3 Drugs classified under this active ingredient

Protein Kinase Inhibitor. Dasatinib 20, 50, 70, 80, 100, 140 mg.
FC tabs:60 X 20,50,70 mg; 30X80,100,140 mg. Recomm. starting dose for chronic phase CML is 100 mg dasatinib dly.
Recomm. starting dose for acceler., myeloid or lymphoid blast phase (adv.   phase) CML or Ph+ ALL is 140 mg once daily. See lit.
Newly diagn. Philadelphia chromos. posit. (Ph+) chron. myelogenous leuk. (CML) in the chron. phase. in adlts.
Chron., accel. or blast phase CML in adlts. with resist. or intoler. to prior ther. includ. imatinib mesilate.
Ph+ acute lymphoblastic leuk. (ALL) and lymphoid blast CML in adlts. with resist. or intol. to prior ther.
C/I:Hypersens.

Tyrosine Kinase Inhibitor. Dasatinib 20, 50, 70, 100 mg.
FC Tabs: 60X 20, 50, 70mg,30X 100 mg. Recomm. starting dose for chron. phase CML is 100 mg dasatinib/d. Recomm. starting dose for accel., myeloid or lymphoid blast phase (adv. phase) CML or Ph+ ALL is 140 mg/d. Tmt. until dis. progress. or until no longer toler. by ptt. Dose incr. or reduct. based on ptt. resp. and tolerab.
Tmt. of adlt pts. with:
• Newly diagn. Philadelphia chrom. positive(Ph+ )
chronic myelogen. leukaemia (CML) in the chron. phase.
• Chronic, acceler. or blast phase CML with
resist. or intoler. to prior ther. incl. imatinib mesilate.
• Ph+ ac. lymphoblastic leukaemia(ALL) and lymphoid blast CML with resist. or intoler. to prior ther.
C/I:Hypersens.

Protein Kinase Inhibitor. Dasatinib 20, 50, 70, 100 mg.
F.C. TABS: 60 x 20, 50, 70 mg. 30 x 100mg.
To be swallowed whole. Adults (from
18 yrs): Chronic phase CML: 100 mg dly
with/out food. Accelerat. myeloid/
lymphoid blast phase CML or Ph+ALL:
70 mg 2 x dly.
Adult, chronic, accelerat. or blast phase
CML with resistance/ intolerance to prior
therapy incl. imatinib mesilate. Adults,
Philadelphia chromosome positive (Ph+)
ALL and lymphoid blast CML with
resistance/intolerance to prior therapy.
C/I: Hypersens., pregn., lact.